; (2) $500,000,000 for fiscal year 2021; (3) $500,000,000 for fiscal year 2022; (4) $500,000,000 for fiscal year 2023; (5) $500,000,000 for fiscal year 2024; (6) $500,000,000 for fiscal year 2025; (7) $500,000,000 for fiscal year 2026; (8) $500,000,000 for fiscal year 2027; (9) $500,000,000 for fiscal year 2028; and (10) $500,000,000 for fiscal year 2029. 3437. Additional funding for the National Institutes of Health There is authorized to be appropriated to the National Institutes of Health for the purpose of conducting research on addiction and pain, including research to develop overdose reversal drug products, non-opioid drug products and non-pharmacological treatments for addressing pain and substance use disorder, and drug products used to treat substance use disorder— (1) $700,000,000 for fiscal year 2020; (2) $700,000,000 for fiscal year 2021; (3) $700,000,000 for fiscal year 2022; (4) $700,000,000 for fiscal year 2023; (5) $700,000,000 for fiscal year 2024; (6) $700,000,000 for fiscal year 2025; (7) $700,000,000 for fiscal year 2026; (8) $700,000,000 for fiscal year 2027; (9) $700,000,000 for fiscal year 2028